Statera Biopharma Reports Net Loss of $14.6 Million for the Third Quarter of 2022

Statera Biopharma, Inc. (STAB) has announced its financial results for the third quarter ended September 30, 2022. The company reported a net loss of $14.6 million for the quarter, reflecting the challenges faced by the biopharmaceutical industry. Despite these difficulties, Statera Biopharma generated revenue of $670,473 during the same period.

Net Loss and Operating Performance

During the third quarter of 2022, Statera Biopharma reported a net loss of $14.6 million. This figure represents a significant decline compared to the previous quarter. The loss is attributed to various factors, including increased operating expenses and other expenses incurred by the company.

Statera Biopharma's operating expenses for the quarter amounted to $2.05 million. These expenses primarily included research and development costs, sales and marketing expenses, and general and administrative expenses. The company is continuously investing in research and development activities to drive innovation in the biopharmaceutical sector.